Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome

NCT02550080 is registered in ClinicalTrials.gov with Shandong Provincial Institute of Dermatology and Venereology as lead sponsor.

NCT NCT02550080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02550080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome
Lead sponsor
Shandong Provincial Institute of Dermatology and Venereology
Phase
Phase 4
Overall status
Unknown status
Start date
July 31, 2015
Completion date
May 31, 2019
Enrollment
3,130 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acne, allergic cutaneous vasculitis, bullous skin diseases, leprosy, pneumocystis pneumonia, psoriasis, sterile pustulosis, urticaria